AI-based mammography tool earns FDA nod

A women’s health technology company has received the FDA’s blessing to market deep learning-based software designed to help breast radiologists spot hard-to-find nascent cancers in 3D mammograms.

Hologic announced the win this week, saying its Genius AI cancer-detection product will supply stronger sensitivity than its predecessor while sharply reducing false positives.

The new software “delivers key metrics at the time of image acquisition to help radiologists categorize and prioritize cases by complexity and expected read time in order to optimize workflow and expedite patient care,” Hologic says.

The company adds that the new product is the only AI-powered offering in its market category that doesn’t require a dedicated server.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup